Crystallized nano-sized alpha-tricalcium phosphate from amorphous calcium phosphate: microstructure, cementation and cell response
Source abstract
Abstract
New insight on the conversion of amorphous calcium phosphate (ACP) to nano-sized alpha tricalcium phosphate (α-TCP) provides a faster pathway to calcium phosphate bone cements. In this work, synthesized ACP powders were treated with either water or ethanol, dried, crystallized between 700 and 800 °C, and then cooled at different cooling rates. Particle size was measured in a scanning electron microscope, but crystallite size calculated by Rietveld analysis. Phase composition and bonding in the crystallized powder was assessed by x-ray diffraction and Fourier-transform infrared spectroscopy. Results showed that 50 nm sized α-TCP formed after crystallization of lyophilized powders. Water treated ACP retained an unstable state that may allow ordering to nanoapatite, and further transition to β-TCP after crystallization and subsequent decomposition. Powders treated with ethanol, favoured the formation of pure α-TCP. Faster cooling limited the growth of β-TCP. Both the initial contact with water and the cooling rate after crystallization dictated β-TCP formation. Nano-sized α-TCP reacted faster with water to an apatite bone cement than conventionally prepared α-TCP. Water treated and freeze-dried powders showed faster apatite cement formation compared to ethanol treated powders. Good biocompatibility was found in pure α-TCP nanoparticles made from ethanol treatment and with a larger crystallite size. This is the first report of pure α-TCP nanoparticles with a reactivity that has not required additional milling to cause cementation.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Dental materials and restorations · Endodontics and Root Canal Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. 10.1007/BF0005333710.1007/BF00053337 ↗
2. 10.1111/j.1551-2916.2004.01126.x10.1111/j.1551-2916.2004.01126.x ↗
3. 10.1016/j.biomaterials.2004.08.00110.1016/j.biomaterials.2004.08.001 ↗
4. 10.1111/j.1551-2916.2010.03856.x10.1111/j.1551-2916.2010.03856.x ↗
5. 10.1007/BF0201754310.1007/BF02017543 ↗
6. 10.1016/j.actbio.2010.02.01710.1016/j.actbio.2010.02.017 ↗
7. 10.1021/ie50278a00710.1021/ie50278a007 ↗
8. 10.1016/j.actbio.2011.06.01910.1016/j.actbio.2011.06.019 ↗
9. 10.1016/j.materresbull.2007.04.01610.1016/j.materresbull.2007.04.016 ↗
10. 10.1016/j.injury.2011.06.01310.1016/j.injury.2011.06.013 ↗
11. 10.1016/j.materresbull.2009.05.01210.1016/j.materresbull.2009.05.012 ↗
12. 10.1111/j.1151-2916.1999.tb02160.x10.1111/j.1151-2916.1999.tb02160.x ↗
13. 10.1016/S0009-2614(03)00505-010.1016/S0009-2614(03)00505-0 ↗
14. 10.1007/s10856-011-4283-x10.1007/s10856-011-4283-x ↗
15. 10.1023/A:101434781424110.1023/A:1014347814241 ↗
16. 10.1016/S8756-3282(99)00143-X10.1016/S8756-3282(99)00143-X ↗
17. 10.1016/j.actbio.2009.03.01110.1016/j.actbio.2009.03.011 ↗
18. 10.1002/jbm.b.3183310.1002/jbm.b.31833 ↗
19. 10.1002/jctb.503032020610.1002/jctb.5030320206 ↗
20. 10.1016/j.cap.2009.04.01410.1016/j.cap.2009.04.014 ↗
21. 10.1111/j.1151-2916.1998.tb02499.x10.1111/j.1151-2916.1998.tb02499.x ↗
22. 10.1002/(SICI)1097-4636(199602)30:2 < 261::AID-JBM17 > 3.0.CO;2-P10.1002/(SICI)1097-4636(199602)30:2 < 261::AID-JBM17 > 3.0.CO;2-P ↗
23. 10.1016/j.tca.2007.11.02210.1016/j.tca.2007.11.022 ↗
24. 10.1016/j.actbio.2006.07.00310.1016/j.actbio.2006.07.003 ↗
25. 10.1039/b210900j10.1039/b210900j ↗
26. 10.1051/rphysap:0197700120506910010.1051/rphysap:01977001205069100 ↗
27. Taut T · Mater. Struct. · 1998 · 5 · 57
28. 10.1016/j.actbio.2012.11.02810.1016/j.actbio.2012.11.028 ↗
29. 10.1016/S0142-9612(98)00131-810.1016/S0142-9612(98)00131-8 ↗
30. 10.1007/s10616-009-9183-210.1007/s10616-009-9183-2 ↗
31. 10.1002/jbm.b.3279410.1002/jbm.b.32794 ↗
32. 10.1002/(SICI)1097-4636(19980305)39:3 < 407::AID-JBM9 > 3.0.CO;2-N10.1002/(SICI)1097-4636(19980305)39:3 < 407::AID-JBM9 > 3.0.CO;2-N ↗
33. 10.1016/j.jnoncrysol.2010.09.01910.1016/j.jnoncrysol.2010.09.019 ↗
34. 10.1016/0003-9861(68)90371-810.1016/0003-9861(68)90371-8 ↗
35. 10.1080/0038701980800743910.1080/00387019808007439 ↗
36. Alobeedallah H · Trends Biomater. Artif. Organs · 2011 · 25 · 12
37. 10.1016/j.msec.2011.05.01210.1016/j.msec.2011.05.012 ↗
38. 10.1016/j.actbio.2009.05.02410.1016/j.actbio.2009.05.024 ↗
39. 10.1111/j.1151-2916.2001.tb00663.x10.1111/j.1151-2916.2001.tb00663.x ↗
40. 10.4028/www.scientific.net/KEM.604.21210.4028/www.scientific.net/KEM.604.212 ↗
41. 10.1016/j.jcrysgro.2012.04.04110.1016/j.jcrysgro.2012.04.041 ↗
42. 10.1021/ja994286n10.1021/ja994286n ↗
43. 10.1016/j.jmatprotec.2007.10.00410.1016/j.jmatprotec.2007.10.004 ↗
44. Bohner M · Eur. Cells Mater. · 2010 · 20 · 110.22203/eCM.v020a01 ↗
45. 10.1177/0022034597076004120110.1177/00220345970760041201 ↗
46. 10.3390/jfb404020910.3390/jfb4040209 ↗